These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23396481)

  • 1. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
    Schwarzenböck S; Sachs D; Souvatzoglou M; Schuster T; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler S; Schwaiger M; Senekowitsch-Schmidtke R; Krause BJ
    Nuklearmedizin; 2013; 52(4):141-7. PubMed ID: 23396481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
    Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
    Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
    Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
    Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
    Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
    Schwarzenböck SM; Gertz J; Souvatzoglou M; Kurth J; Sachs D; Nawroth R; Treiber U; Schuster T; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Henriksen G; Wester HJ; Krause BJ
    Mol Imaging Biol; 2015 Apr; 17(2):248-56. PubMed ID: 25163420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
    Müller SA; Holzapfel K; Seidl C; Treiber U; Krause BJ; Senekowitsch-Schmidtke R
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1434-42. PubMed ID: 19352653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
    Sutinen E; Nurmi M; Roivainen A; Varpula M; Tolvanen T; Lehikoinen P; Minn H
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):317-24. PubMed ID: 14628097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy.
    Giovacchini G; Picchio M; Coradeschi E; Scattoni V; Bettinardi V; Cozzarini C; Freschi M; Fazio F; Messa C
    Eur J Nucl Med Mol Imaging; 2008 Jun; 35(6):1065-73. PubMed ID: 18200444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.
    Hara T; Bansal A; DeGrado TR
    Nucl Med Biol; 2006 Nov; 33(8):977-84. PubMed ID: 17127170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies.
    Nanni C; Pettinato C; Ambrosini V; Spinelli A; Trespidi S; Rubello D; Al-Nahhas A; Franchi R; Alavi A; Fanti S
    Nucl Med Commun; 2007 Jul; 28(7):547-53. PubMed ID: 17538396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
    Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
    J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.
    Oyama N; Ponde DE; Dence C; Kim J; Tai YC; Welch MJ
    J Nucl Med; 2004 Mar; 45(3):519-25. PubMed ID: 15001697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
    Li X; Liu Q; Wang M; Jin X; Liu Q; Yao S; Liu S; Li J
    Clin Nucl Med; 2008 Oct; 33(10):671-6. PubMed ID: 18806565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR-guided focused ultrasound: enhancement of intratumoral uptake of [³H]-docetaxel in vivo.
    Chen L; Mu Z; Hachem P; Ma CM; Wallentine A; Pollack A
    Phys Med Biol; 2010 Dec; 55(24):7399-410. PubMed ID: 21098923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.